Replies to post #9737 on OncoSec Medical Inc (ONCSQ)

[trading.jeff]

Thanks for posting. Here are some important excerpts:

Last month, the Swiss drug company Novartis AG acquired immunotherapy company CoStim Pharmaceuticals in Cambridge for an undisclosed amount. And Agenus Inc. in Lexington recently announced it had acquired 4-Antibody AG, a European firm focused on developing immune-stimulating therapies.

...

Building on discoveries by a Japanese scientist, Gordon Freeman at Dana-Farber led work in the early 2000s to identify two molecules that bind to a protein called PD-1 and signal the immune system to stand down.

...

“These [PD-1 blocking] drugs are basically already on the map,” said Dr. Keith Flaherty, a melanoma specialist at Massachusetts General Hospital Cancer Center who has been treating Eckert. “Not one of them is FDA-approved yet, but we have seen enough evidence in our patient trials to say this is a quantum leap.”

There is plenty of room for multiple players in the treatment of melanoma. The key question that makes OncoSec stand out from the rest is: "Why did Dr. Pierce choose OncoSec over other companies?" With his background, it is almost a slam dunk that he is well aware of all the research, trials, and results in the treatment of melanoma.

IMO.

$ONCS

[DDJ]

Good stuff Ckbike! New Brian Nichols article just out, http://seekingalpha.com/article/2078083-is-oncosec-medical-set-to-trade-even-higher